je.st
news
Tag: on
G.I. Joe Inventor Sues to Break Hasbro's Kung-Fu Grip on...
2015-09-17 03:48:27| Toys - Topix.net
Toy giant Hasbro is being sued by a man who claims to have created the iconic action figure, and who wants the copyright returned to him. In a suit filed Tuesday, Stanley A. Weston claimed that in 1963 he created the idea for male action figures "wearing and carrying miniaturized versions of the uniforms, insignias, emblems and equipment of each of the different branches of the United States armed forces."
U.S. forestry shipments softening impact of weak commodities on CN
2015-09-17 00:56:20| Railroads - Topix.net
Amid weak commodity markets and a shaky domestic economy that have hammered freight volumes, Canada's largest railway is counting on the resilient U.S. economy to help it post double-digit earnings growth. , said forestry carloads for the U.S. housing industry and automotive shipments are helping offset poor demand for coal, grain and oil.
Tags: on
impact
weak
commodities
With the U.S. real estate market bordering on "booming", now is the time to get in on the action.
2015-09-16 18:38:39| Real Estate - Topix.net
NEW YORK -- The U.S. economy has been pitching and rolling in turbulent financial waters over the past few years, but one area where indisputable progress is being made is in the residential real estate market. Case in point - Savills's most recent World Residential Market report notes that, based on a formula of "broad economic and demographic factors," the U.S. is a "clear number one" country for investing in real estate.
Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
2015-09-16 16:16:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: on
type
similar
controlled
It is broad, looks fabulous and is based on nothing.
2015-09-16 14:07:00| Trucking - Topix.net
Really, this is a rally based on negativity -- lots of shorts ahead of the meeting, panicking on the possibility that China dives again and that the manufacturing data is so weak. We are seeing the classic growth stocks continue to rally based on the possibility that there is no Fed rate hike.
Sites : [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] next »